Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of SAR448501/DR-0201 as Multiple Ascending Doses in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

NCT06392477 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06392477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06392477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of SAR448501/DR-0201 as Multiple Ascending Doses in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Recruiting
Start date
July 8, 2024
Completion date
February 11, 2028
Enrollment
96 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non hodgkin lymphoma